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ABSTRACT
Signal transducers and activators of transcription 5 (STAT5a and STAT5b) are highly 
homologous proteins that are encoded by two separate genes and are activated by Janus-
activated kinases (JAK) downstream of cytokine receptors. STAT5 proteins are activated by 
a wide variety of hematopoietic and non-hematopoietic cytokines and growth factors, all of 
which use the JAK-STAT signalling pathway as their main mode of signal transduction. 
STAT5 proteins critically regulate vital cellular functions such as proliferation, 
differentiation and survival.  The physiological importance of STAT5 proteins is underscored 
by the plethora of primary human tumours that have aberrant constitutive activation of these 
proteins, which significantly contributes to tumour cell survival and malignant progression of 
disease. 
STAT5 plays an important role in the maintenance of normal immune function and 
homeostasis, both of which are regulated by specific members of IL-2 family of cytokines, 
which share a common gamma chain (γc) in their receptor complex. STAT5 critically 
mediates the biological actions of members of the γc family of cytokines in the immune 
system. Essentially, STAT5 plays a critical role in the function and development of Tregs and 
consistently activated STAT5 is associated with a suppression in antitumour immunity and an 
increase in proliferation, invasion and survival of tumour cells. Thus, therapeutic targeting of 
STAT5 is promising in cancer.
2
The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway 
represents an extremely rapid membrane to nucleus signalling system mediating cytokine 
signals in mammals [1, 2]. It was studies on the interferon (IFN) receptor signalling that led 
to the discovery of the JAK-STAT pathway [3]. The JAK–STAT signalling is induced by 
engagement of a ligand (eg. cytokine) to its corresponding transmembrane receptor. This 
leads to dimerization of the receptor and thereby activation of receptor-associated JAKs, 
which subsequently phosphorylate tyrosine residues present in the cytoplasmic domain of the 
receptor. Phosphorylated tyrosine residues serves as docking sites for the src-homology2 
(SH2) domains in STATs. The STATs are then phosphorylated by activated JAKs at a single 
tyrosine residue in the C terminus. Tyrosine-phosphorylated STATs form homo or 
heterodimers via reciprocal phosphotyrosine (pTyr)-SH2 interactions and are immediately 
translocated to the nucleus where they bind to palindromes of the general form TTC(N2–
4)GAA, termed γ activated sequences (GAS). The STATs are dephosphorylated by nuclear 
tyrosine phosphatases and exported to the cytoplasm to efficiently continue the 
phosphorylation-dephosphorylation cycle. Although recent studies on the STAT proteins 
have demonstrated constitutive energy and transport factor independent shuttling of STATs 
between the nucleus and cytoplasm [4, 5], it is due to the specific conformation of tyrosine 
phosphorylated dimers that enables retention in the nucleus and the binding of STzATs to 
respective GAS sequences [4]. Recent studies have suggested a role for dephosphorylated 
STAT in the nucleus in maintaining the stability of transcriptionally repressed 
heterochromatin [6]. 
STATs and protein structure
 The first STATs to be cloned by Darnell and co-workers were the IFN-inducible 91-kDa 
STAT1and the 113-kDa STAT2 proteins [3, 7]. The remaining five STATs were identified 
subsequently. There are seven STAT proteins in mammals, STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6, with molecular masses between 75 and 95 kDa and 
all are mapped to 3 chromosomal clusters being indicative of a common ancestral gene [8]. 
Out of the seven STATs,  STATs 1, 3, 5A, and 5B can be activated by an array of cytokines 
including growth factors (EGF, PDGF, Hepatocyte growth factor, insulin-like growth factor, 
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colony stimulating factor–1, Erythropoietin) and hormones (Prolactin, Growth hormone, 
Insulin) as well as downstream of some G-protein coupled receptors [1, 9, 10]. STATs 2, 4 
and 6 are activated by a smaller subset of cytokines (IFN-α, IL-12 and IL-4/IL-13 
respectively). 
All STAT proteins contain a conserved common structure containing the following domains: 
the N terminal domain (NTD), coiled-coil domain (CCD), src homology-2 (SH2) domain, 
linker domain (LD), DNA binding domain (DBD) and a transactivation domain (TAD) at the 
extreme C-terminus [11]. The conserved N-terminal domain is involved in protein-protein 
interactions [12], and allows for cooperativity  in dimer-dimer interactions and/or to form 
tetramers that can then bind to non consensus sites [13-15].  The NTD is conserved among 
the STATs, and it is 91% similar in the human STAT5a and STAT5b. Crystallographic 
studies on N-terminus of STAT4 revealed that it is composed of eight helices with a hook-
like structure, which promote oligomerization of STAT dimers [16] and binding to tandemly-
linked GAS sites [14, 17, 18]. Loss of cooperative STAT binding to tandem GAS sequences 
was observed due to mutation of a conserved tryptophan at position 37 to alanine (W37A), in 
STAT1, STAT4, STAT5a and STAT5b [15, 16], and furthermore in a loss of cytokine-
induced phosphorylation of the critical tyrosine residue in the SH2 domain of STAT4 only 
[19]. Thus, the NTD serves a common function for all STAT proteins, which is to facilitate 
cooperative binding to tandemly-linked sites, and a selective role in the receptor-mediated 
activation of STAT4. Recently, an alternative more thermodynamically stable dimer interface 
for NTD interactions was determined, which identifies a conserved phenylalanine residue 
(F77 in STAT1, and F81 in STAT5) as being the critical residue [20]. As with W37A, 
mutation of this residue in STAT1 and STAT5 leads to a loss of tetramer, but not dimer 
formation on DNA [4]. Other functions of the NTD include its role in promoting protein-
protein interactions such as binding of CBP/p300 to STAT1, receptor domains and PIAS 
family proteins [19, 21, 22].
The CCD binds to other transcription factors and coactivators [16, 23] and is implicated in 
nuclear translocation and retention of STAT3 [24] as well as nuclear export of STATs [25]. 
The DBD, as the name suggests, mediates the binding of STATs to target sites with the 
canonical  GAS sequence TTCN3-4GAA and defines the binding specificity [26-28], although 
the same is not the case with STAT2 [29]. Immediately following the DBD is a linker 
domain, which connects the DBD and the SH2 domain. The highly conserved SH2 domain 
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interacts reciprocally with phosphorylated tyrosine residues on receptors, and thus has a role 
both in receptor docking and STAT dimerization [11]. The STAT family of proteins are 
phosphorylated at tyrosine and/or serine residues except STAT2, which is not known to be 
serine phosphorylated [30-32].  The variable TAD at the C- terminus is critical for 
transcriptional activation and interacts with additional co-factors [33]. The C-terminus of 
STAT1, STAT2, STAT5a, STAT5b and STAT6 interact with CBP/p300 [22, 34-36]. 
Recently it was proved that the DNA replication factor MCM5 which interacts with the C-
terminus of STAT1 is essential for STAT1-mediated transcriptional activation [37]. STATs 
have also been shown to associate with AP1, IRF-1, NF-kB, Sp1, c-Jun, USF-1, Pu.1 and 
also with the glucocorticoid receptor [38-40]. 
STAT5
The transcription factor STAT5, was initially identified as a prolactin activated ovine 
mammary gland factor (MGF) [41]. Studies directed at IL-3 induced signal transduction and 
cloning, led to the discovery of two highly related isoforms, STAT5a and STAT5b [42, 43]. 
STAT5a is the major STAT5 isoform in the mammary gland, whereas STAT5b is the major 
STAT5 isoform in the liver. While STAT5a is mainly responsible for PRL dependent 
mammary gland development and function [44], STAT5b is required to maintain normal 
sexually dimorphic GH responses [45]. In humans, the genes for STAT5a and STAT5b map 
to chromosome 17q11.2, share 91% homology at the amino acid level and differ primarily at 
their C terminus [8, 42, 43, 46]. Obvious structural differences between the two forms of 
STAT5 include an additional 12 amino acids on the carboxy-terminus of STAT5a, which 
gives rise to a slightly shorter STAT5b and a 5 residue abbreviation of the STAT5a 
phosphotyrosyl tail segment between the SH2 and TAD domains. 
Modulation and regulation of STAT5 function
 STAT5 can be activated by a diverse group of cytokines, which include prolactin, growth 
hormone, erythropoietin (Epo), thrombopoietin (Tpo), granulocyte-macrophage colony-
stimulating factor (GM-CSF), epidermal growth factor (EGF), IL-2, IL-3, IL-5, IL-7, IL-9 
and IL-15 [47, 48] and requires specific kinases (Table 1). The STAT5 signalling pathway is 
a transient and tightly regulated process, although less is known of the signals leading to its 
inactivation. The duration of activation of STAT5 is evident within minutes of cytokine 
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stimulation and disappears a couple of hours later. However, it is found to be constitutively 
active in numerous primary human tumors, leukemias, and myeloproliferative disorders 
(MPDs) [49]. STAT5 function is regulated by post-translational modifications, members of 
SOCS family, PIAS family, caveolins, phosphatases and various protein-protein interactions. 
STAT5 signalling is mediated by mechanisms that involve direct and indirect manipulation of 
STAT5 activity. STATs can be post-translationally modified by acetylation, ubiquitylation, 
glycosylation, ISGylation, sumoylation and the most common being phosphorylation [50, 
51]. Post-translational modification can lead to STAT5 being either positively or negatively 
regulated.
Tyrosine phosphorylation
STAT5 is activated by tyrosine phosphorylation at position 694 and 699 for STAT5a and 
STAT5b respectively and can be negatively regulated by dephosphorylation. Tyrosine 
phosphosphorylation is crucial for STAT5 activity and can be phosphorylated by receptor 
associated JAKs as well as non-receptor Src kinases. Unlike JAKs, activation of STAT5 by 
Src kinases, leads to the translocation of only STAT5b into the nucleus [52]. Recent studies 
suggest a role for the src family of kinases (SFK)-STAT5 pathway in transformations and 
malignancies [53]. While a number of protein tyrosine kinases have been shown to 
phosphorylate STAT5, the phosphatases responsible for STAT5 dephosphorylation in-vivo 
remain elusive, despite a number of studies on candidate protein tyrosine phosphatases (PTP), 
including SHP-1, PTP1B, SHP-2, CD45, T-cell PTP (TC-PTP) and phosphatase 2A, which 
have been shown to dephosphorylate STATs in vitro [54-58]. Overexpression of PTP1B 
leads to dephosphorylation of STAT5 [57]. SHP-2 is a STAT5a phosphatase involved in 
dephosphorylation of the tyrosine-phosphorylated STAT5a in the cytoplasm [20]. Recently it 
has been shown that the small dual-specificity phosphatase “VHR (Vaccinia H1 Related)” 
dephosphorylates tyrosine-phosphorylated STAT5, subsequently inhibiting STAT5 function 
[59]. The phosphorylation of VHR is required to activate its phosphatase activity toward 
STAT5 [59]. The possibility of other unidentified nuclear phosphatase(s) that 
dephosphorylates STAT5 still exists. Nevertheless, phosphorylated STAT5 proteins are 
known to be targeted for degradation via the ubiquitin-mediated proteasomal degradation 
pathway [60, 61]. 
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Serine phosphorylation
In addition to tyrosine phosphorylation, STAT5a and STAT5b are also induced to undergo 
serine phosphorylation [1]. Phosphorylation of serine residues is independent of tyrosine 
phosphorylation. Mutational studies on mouse Stat5 genes and the development of phospho 
specific antibodies helped to identify serine phosphorylation sites in a conserved PSP motif 
of Ser725 for STAT5a and Ser730 for STAT5b [62]. Serine phosphorylation at the S725 and 
S779 residues of STAT5a cooperate to negatively regulate PRL-induced transcription of ß-
casein in the absence of costimulation of the glucocorticoid receptor [63]. The biological and 
physiological implications of STAT5 serine phosphorylation are not completely understood, 
though a study on expression of p21-activated kinase (Pak1), a serine/threonine protein 
kinase, showed that it associates with STAT5 and phosphorylates STAT5a at serine position 
S779 and thereby stimulates ß-casein promoter activity [64]. Clark et al have identified a 
novel STAT5a serine phosphorylation at S127/128 which is critical for ERBB4-induced 
STAT5a stimulation and phosphorylation at S779 is regulated by ERBB4 expression in 
mammary glands [65]. 
Friedbichler et al in 2010 demonstrated that serine phosphorylation plays an improtant role in 
leaukemogenesis [66]. More recently, it has been shown that serine phosphorylation leads to 
nuclear transport of STAT5 in BCR-ABL induced disease (chronic myeloid leukemia) [67]. 
Glycosylation
STAT5 can be post-translationally modified by glycosylation. A study on HC-11 mammary 
epithelial cells has reported glycosylation of STAT5a by O-linked N acetyglucosamine (O-
GlcNAc) following STAT5 activation and the glycosylated form is mainly found in the 
nucleus of hormone-induced cells [68]. The glycosylation occurs at the N- terminal threonine 
T92 position [68]. A mutation at T92 led to loss of STAT5 glycosylation and thereby its 
ability to bind the transcriptional coactivator CBP. Studies done by Nanashima et al went 
onto demonstrate that STAT5a was modified by O-GlcNAc in the Hirosaki hairless rat 
(HHR) and was identified in the nucleus [69]. Additionally, the glycosylated STAT5a was 
shown to bind to the STAT5-responsive element with an enhanced affinity. 
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SUMOylation and PIAS
SUMO is an ubiquitin-related molecule and protein-SUMO conjugation (Sumoylation) has 
been found to have various functions, including positive and negative regulation of STAT 
transcriptional activity. There are three forms of SUMO peptide, namely SUMO1, SUMO2 
and SUMO3, and they consist of around 100 amino acids, which are added to a consensus 
sumoylation site ( KXE). SUMOylation is catalyzed by SUMO-specific E1, E2, and E3 
ligases and can be reversed by SUMO-specific proteases (SENPs). Sumoylation has been 
shown to modify protein function by altering the function, localization and extent of 
ubiquitination [70]. ICA512 which is a catalytically inactive member of the receptor protein 
tyrosine phosphatase (PTP) family, mediates the binding of PIASy to STAT5 and 
sumoylation of ICA512 regulates its binding to STAT5 [71]. Recently, Van-Nguyen et al 
have shown that the activity of STAT5 is inhibited upon active SUMOylation of STAT5. 
This was due to an absence of SENP1 and thus, SENP1 played a role in the SUMOylation 
and regulation of STAT5 transcription during lymphoid development [72].
Originally discovered as negative regulators of STAT signalling, the mammalian protein 
inhibitors of activated STATs (PIAS) family consists of 5 members, PIAS1, PIAS3, PIASxα, 
PIASxβ and PIASY [21]. Although several molecular mechanisms have been proposed to 
explain transcriptional regulation by PIAS proteins, the ones of interest for STAT5 are: PIAS 
may repress transcription by inhibiting the DNA-binding activity of STAT5 or PIAS may 
regulate transcription by promoting sumoylation of STAT5. Thus, it was observed by 
Rycyzyn and Clevenger, that overexpression of PIAS3 in CHO cells represses STAT5 
transcriptional activity [73]. Recently, a functional role for the E3 ubiquitin ligase c-Cbl was 
demonstrated in differentiation of osteoblasts and that blocking c-Cbl activity, downregulates 
STAT5 ubiquitination and promotes bone regeneration [74]. 
Transcriptional co-activators of STAT5
A number of proteins are known to interact with STAT family members and interaction of 
STAT5 with additional proteins including transcription factors and co-activators regulates its 
activity. Transcriptional initiation requires the interaction of STAT5 with the initiation 
complex in addition to co-regulatory proteins. These co-activators mainly interact with the 
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TAD of STAT5, although they are also known to interact via the CCD and SH2 domains. The 
interaction of STAT5 with other nuclear factors presents a regulatory mechanism that 
determines greater potency of signalling and/or greater selectivity of target genes [35]. One of 
the first studied factors was CBP which is the binding protein for cAMP response element 
binding protein (CREB). CBP and p300 interact with the TAD of STAT5 [75]. Nuclear 
receptor co-activator 1 (NCoA-1) binds to the TAD domain of STAT5a and is essential for 
the transcriptional activity of STAT5a [76]. N-myc interacting protein (Nmi) is another 
STAT5 interacting protein that augments the recruitment of CBP/p300 to STAT5 [35]. The 
glucocorticoid receptor (GR) has been reported to interact with the N terminus of STAT5 and 
is required for many functions exerted by either transcription factors [77]. GR binds to 
STAT5a and has a physiological significance in the expression of  milk protein genes [78]. A 
list of some of the known protein interactions with STAT5 are listed in Table 2.
Interaction of STAT5 to DNA binding sites
The STAT5 proteins interact directly with specific DNA elements through the DNA binding 
domain in the center of the STAT5 structure along with cooperation of all the other domains. 
The SH2 domain of STAT plays a vital role in the dimerization [79], and gene regulation of 
STAT5 may be influenced by the pattern of STAT5a and STAT5b pairing as homo or 
heterodimers [80-82]. It is known that DNA binding requires dimerization, which is mediated 
by phosphotyrosyl-SH2 domain interactions between two STAT5 proteins. STAT5 forms 
supramolecular complexes (dimer-dimer or higher) on target sites containing two or more 
neighbouring STAT binding sites [4, 15]. 
STAT dimers can undergo tandem linkage through their N terminal domains when bound to 
closely spaced GAS sites [17]. STAT5a and STAT5b exhibit differences with respect to their 
tissue distribution [42, 43]. Park and Waxman in 2001 were able to prove that 
heterodimerized (STAT5a-STAT5b) and homodimerized (STAT5b-STAT5b) STAT5 
complexes play distinct roles in the sexually dimorphic responses of the liver to growth 
hormone [83]. It has previously been reported that cytokines cause tyrosine phosphorylation 
and DNA binding of predominantly one STAT5 protein (STAT5a) despite ample expression 
of both forms of STAT5 in certain cell contexts [84]. One study reported different DNA 
binding specificities for STAT5a homodimers versus that of STAT5b homodimers due to a 
single amino acid change in DNA binding domains of the two proteins [85]. However, 
generally there are no significant differences in DNA binding specificity between STAT5a 
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and STAT5b [86-88]. The consensus STAT5a and STAT5b binding sites that have been 
defined in vitro are TTCYNRGAA and TTC(T/C)N(G/A)GAA [86, 89]. The STAT5 
alignment matrix prepared by Fung et al also favours the consensus GAS motif 
TTC(T/C)N(G/A)GAA [90]. 
Previous studies have established a role of the N terminal domain of STAT proteins in 
formation of tetrameric complexes [16, 18]. STAT5 tetramer formation does not require high 
affinity sites, and binding of STAT tetramers to weak binding sites produced even more 
stable complexes than single dimers bound to high affinity sites [15, 16]. Purified STAT5a 
has a higher DNA binding affinity and could bind to chromatin in the tetrameric form 
compared to STAT5b which preferentially bound to chromatin as dimers [86]. Tetramer 
competent STATs could have a wider range of potential DNA binding sites [15, 86]. The 
importance of tetramerization of STAT5 was shown for the transcriptional activation of 
CD25 promoter [4, 15]. Tetramerization of STAT5 has been associated with leukemogenesis 
[91]. A constitutively active STAT5a mutant (cS5F) increased the abundance and stability of 
STAT5 tetramers compared to the unmutated form and N terminal mutations directed at only 
tetramer formation failed to induce leukaemia, suggesting that tetrameric STAT5 complexes 
may regulate a different subset of target genes some of which drive tumorigenesis [91]. A 
recent study, in STAT5a-Stat5b double knock-in (DKI) mice that form dimers but not 
tetramers, identified genes regulated by STAT5 tetramers, in addition to defining the 
consensus sequences required by dimers versus tetramers [92]. The study shows that 
tetramerization is critical for normal immune function. 
BIOLOGICAL FUNCTIONS OF STAT5
Despite sharing ~96% homology at the protein level, both Stat5 proteins have overlapping 
and distinct functions. Generation of single and double KOs and transgenic mice for STAT5a 
and Stat5b proteins has greatly enhanced the understanding of the biological roles of these 
proteins. Indeed, most studies investigationg the role of STAT5 in immunity were performed 
on the “STAT5 null mice” that still retained a residual protein lacking the N-terminal domain 
of STAT5, also denoted as the STAT5a/b ΔN/ΔN [44, 93, 94]. However, more recent data have 
been derived from the analysis of STAT5 null mice presenting with a complete deletion of 
the STAT5a/b gene locus, also denoted as STAT5a/b fl/fl, lck-cre and the STAT5a/b null/null 
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mice. The difference between the mouse models STAT5a/b ΔN/ΔN  and STAT5a/b null/null are 
strong and implies classified roles for the N terminal truncated STAT5. 
Role of STAT5 in immunity
STAT5a/b are crucial regulators of the immune system. An initial understanding of its role 
came through knock out mice generated in 1998 which was enhanced upon, by the next 
generation of null mice generated a few years later in 2004 . Thus, the implications of the role 
of STAT5 are derived from two generations of STAT5 ΔN /null mice [94, 95]. 
Studies from the first generation of KO mice (STAT5a/b ΔN/ΔN)
Most studies that investigated the role of STAT5A/B in lymphopoiesis employed the 
STAT5A/ΔN, STAT5B/ΔN and the STAT5A/BΔN/ΔN mice. These STAT5A/ΔN and STAT5B/ΔN 
mice (as well as STAT5A/BΔN/ΔN mice) were viable and revealed surprisingly mild 
phenotypes in the development and function of T and B lymphocytes. The phenotype of the 
STAT5A/BΔN/ΔN mice was expectedly, more severe than either of the single KOs 
(STAT5A/ΔN or STAT5B/ΔN ) alone, and not only showed reduced proliferation of 
splenocytes but also splenomegaly along with reduced number of NK cells and activated 
phenotype of T cells [96].
Upon studying the lymphoid development in STAT5A/BΔN/ΔN double mutant mice, there was 
a subtle reduction in T and B cell numbers, which was accompanied by a complete lack of 
natural killer (NK) cells and CD4+CD25+ suppressor T cells. 
STAT5A/ΔN deficient T cells presented a reduction in the expression of cytokine receptor IL-
2Rα and this was confirmed by the finding that its expression was upregulated by the 
cytokine IL-2 [97]. Studies on STAT5A/ΔN and STAT5B/ΔN mice demonstrated defects in T 
cell proliferation and function [98]. While splenocytes from STAT5A/ΔN mice showed partial 
impairment in IL-2 mediated proliferation, STAT5B/ΔN mice showed even more severe 
defect in proliferation [98, 99]. STAT5A/BΔN/ΔN mice caused impaired proliferation in 
response to IL-2 and halted cell-cycle progression to mature T cells [94, 96, 100]. Both Stat5 
proteins regulate TCR-mediated proliferation of CD4 T cells [96], and a greater defect was 
observed in STAT5B/ΔN than in STAT5A/ΔN mice with regard to reduced number of natural 
killer (NK) cells, suggesting that STAT5a and STAT5b play an unequal role in normal NK 
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cell development [96]. NK cells are absent in STAT5A/BΔN/ΔN mice and there is no cytotoxic 
activity in presence or absence of IL-12 or IL-15 [96]. A role for STAT5 in the survival and 
differentiation of memory CD8 T cells was confirmed by studies using the STAT5A/ΔN and 
STAT5B/ΔN mice, which had reduced numbers of CD8+ T cells from splenocytes and 
transgenic expression of STAT5 resulted in an increase in the number of CD8+ T cells [101]. 
It was studies on allergic late-phase reactions that led Kagami et al to demonstrate that 
STAT5A/ΔN and STAT5B/ΔN mice had reduced CD4+ T cell infiltration along with 
diminished eosinophil recruitment. This was due to defective STAT5 functions in these mice, 
leading to a reduction in antigen mediated proliferation of splenocytes and T cells and a 
subsequent decline in the antigen induced T cell infiltration in the airways [102]. The role of 
STAT5 in T helper cell differentiation was defined on studies using the STAT5A/ΔN mice. 
Th2 cell differentiation from antigen-stimulated splenocytes was significantly decreased in 
STAT5A/ΔN mice suggesting that STAT5a regulates T helper cell differentiation. The 
impairment in Th2 cell differentiation was detected in the presence of high concentrations of 
IL-4, which was restored upon retrovirus-mediated expression of STAT5b. Although 
Friedrich et al noted that STAT5b is a mediator of IL-4 induced cell proliferation [103], a 
role for IL-4 mediated activation of STAT5 was dismissed due to no phosphorylation of 
STAT5a even in the absence of STAT6. There was also an impairment in the development of 
Tregs (CD4+CD25+) in the STAT5A/ΔN mice and a depeletion of the Tregs from 
spelenocytes of these mice did not impair differentiation into Th1 or Th2 cells. Thus, 
STAT5a is essential for the differentiation into Th2 and development of Tregs. 
Additionally, mice deficient in STAT5a/5b demonstrated reduced numbers of peripheral B 
cells and of B-cell precursors in the bone marrow [104].
Studies from the second generation of STAT5 KO mice (STAT5a/b null/null)
Most recent data have been derived from the analysis of STAT5-null mice, in which the 
entire STAT5a/5b locus was flanked by LoxP sites and further deleted by the CRE-mediated 
recombination (using the Cre/Lox technology) [95]. The differences between the two mouse 
models (STAT5A/BΔN/ΔN  and STAT5a/b null/null ) are strong. For instance, STAT5a/b null/null 
lack CD8+ T lymphocytes and failed to develop T, B and NK cells [105, 106]. Moreover, B-
cell development is abrogated at the pre-pro B cell stage in the bone marrow of STAT5a/b 
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null/null mice when compared to the previous truncated version of STAT5A/B/ΔN/ΔN mice. 
These studies lead to an important conclusion of the differences between the two generations 
of KO mice. The truncated versions of STAT5 proteins expressed in the STAT5A/B/ΔN/ΔN 
mice are able to compensate and to a large extent not only resucue B cell development, but 
also support the development of CD8+ T cells. It is now well known that the truncated 
versions of STAT5 can bind to a fraction of the STAT5 target genes within the nucleus, 
thereby activating or repressing them. 
The first evidence of the role of STAT5 in CD8+ T cell differentiation came with studies on 
STAT5b-CA mice which exhibited increased numbers of CD8+ T lymphocytes. This was 
confirmed when Park et al, proved, that strong TCR signals led to a repression in the IL-7R 
which subsequently led to a downregulation of CD8 expression [107]. According to the co-
receptor model, high affinity TCRs differentiate into CD4+ T cells while low affinity TCR’s 
lead to differentiation and expression of CD8+ T cells. Interestingly, the molecular basis of 
this CD8 T cell differentiation was due to a dependance on STAT5 signalling and was 
determined by expressing Runx3, the master regulator for CD8 T cells [108].  Thus, STAT5 
signalling is required in mature CD8+ T cells for the expression of the CD8 master regulator 
Runx3 and CD8 . 
It was Zhu et al, who in 2003 first suggested a role for STAT5 in Th2 differentiation, by 
ectopically expressing activated STAT5[109]. This led to a skewing of the cells from Th1 to 
Th2 fate. These studies demonstrated that expression of STAT5 ectopically, suppressed Th1 
and Th17 differentiation, while promoting Th2 cell differentiation by suppressing the 
production of IFNy. Thus, both STAT5a and STAT5b regulate Th2 cell differentiation. In 
brief, IL-2 regulates Th2 cell differentiation by upregulating GATA3 and an upregulation in 
the IL-4R due to the binding of STAT5 to the promoter of the IL4r [110]. IL-2 via STAT5 
augments and regulates the expression of IL12rb2 and Tbx21, leading to an enhancement in 
Th1 responses as well [111].
Previous work on the STAT5A/BΔN/ΔN mice had demonstrated that Treg numbers were 
reduced in these mice and that activation of STAT5 led to an increase in Tregs. However, 
further work using the STAT5a/b null/null  mice established that conditional deletion of STAT5 
in double positive thymocytes, resulted in decreased numbers of CD8+ T and a failure to 
develop into Tregs [105]. Most importantly, none of the surviving tregs had the deleted 
STAT5 protein, which goes on to support its role in the development of Tregs. This 
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observation was confirmed using STAT5b-CA mice lacking the IL-2Rb, which suggested 
that STAT5 played a crucial role in rescuing Treg development in the IL-2Rb negative mice. 
At the same time, these studies also went onto reveal the binding sites of STAT5 on the 
Foxp3 promoter, which is master regulator of Tregs [112]. 
Role in haematological malignancy
STAT5 activation has been found in blood malignancies (HTLV-1 dependent leukaemia, 
Erythroleukemia, Acute lymphocytic leukaemia (ALL), Acute myelogenous leukaemia 
(AML), Chronic myelogenous leukaemia (CML), megakaryocytic leukaemia (ML)  and 
Hodgkins lymphoma [113-116] and human tumours (breast, prostate, ovary, head and neck 
cancers) [117, 118]. STAT5 has also been shown to be constitutively activated in cutaneous 
lymphomas, while dysregulated expression of a C-terminally truncated form of Stat5 in 
Sezary Syndrome was associated with a loss of IL-2-induced gene expression [119]. 
Although both the STAT5 isoforms have been involved in human cancers and tumors, the 
exact role of each isoform in a specific cancer has not yet been illustrated. 
With the prominent role played by STAT5 in the development, differentiation and survival of 
lymphoid cells, it is no wonder then that it is involved in hematologic malignancies. ALL is a 
neoplastic disease of both children and adults characterised by acquired genetic alteration, 
chromosomal alterations and translocations are factors that lead to the diagnosis and 
prognosis of the disease. Studies on the ABL oncogene demonstrated that the STAT5a/b 
null/null cells are refractory to transformation by the Abelson oncogenes and subsequently fail 
to induce lymphoid leukemia, whereas STAT5A/B/ΔN/ΔN-derived cells are readily 
transformed [105]. Multi-lineage leukemia was also observed in mice expressing the 
constitutively active STAT5a/b which was due to the tetramerization capability of STAT5a/b 
in these mice [91]. Thus, although the truncated version of STAT5 is deficient in the 
tetramerization domain, they are able to compensate for the loss by binding to oncogenic 
tyrosine kinases (eg ABL oncogene). Xia et al, demonstrated that the naturally occurring 
truncated forms of STAT5 were responsible for blood cell cancers and was the main cause 
for the relapse of the cancer [120]. The role of STAT5 in ALL was confirmed when, 
Nakayama et al, found that STAT5b-CA mice developed symptoms closely related to human 
pre-B ALL [121]. Another set of studies also demonstrated that a transgenic STAT5-CA 
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mouse presented with loss of p53 and concurrent initiation of B cell leukemia [122]. Lessons 
learnt from a limited study of human samples also supported the evidence and that STAT5 
was constitutively activated in more than 60% of frozen ALL samples [123, 124]. 
A classic example of the complex nature of the cascade of signalling pathways that can be 
activated by a single oncogenic protein in cancers is that of signalling mediated through the 
Bcr-Abl tyrosine kinase, which also induces constitutive STAT5 activation in CML [117]. 
Studies on mice suggested that Stat5 was not required for the induction of BCR-ABL-
induced CML-like leukemia [104]. In contrast, recent studies showed that STAT5 is required 
for the development of leukemia upon introduction of BCR-Abl [105]. In the absence of 
STAT5a, the incidence of CML was reduced [125]. Serine phosphorylation of STAT5 is 
essential for leukemogenesis and serine phosphorylation of STAT5a is necessary for nuclear 
localization of STAT5 in BCR-Abl+ cells and that formation of tetramers rather than dimers 
is associated with leukemogenesis  [66, 91]. Furthermore, a recent study demonstrated that 
BCR-ABL1 aftects STAT5A/B differentially.  Using a BCR-ABL positive cell line, STAT5B 
RNAi knock down led to sensitization of leukemic cells to treatment by imatinib [126], and 
STAT5A attenuation enhanced the basal oxidative stress and DNA damage of normal CD34 
positive and CML cells. Attenuation of STAT5a also resulted in the inhibition of growth in 
CD34 positive CML cells from imatinib resistant patients [127]. 
CML is a clonal hematopoietic stem cell (HSC) malignancy characterized by chromosomal 
translocation and the hallmark oncogenic event is the formation of the mutant BCR-ABL and 
activation of STAT5 [115]. Indeed, BCR-ABL1 is crucial for the survival and proliferation of 
leukemic cells in chronic stage CML and Hochhaus  et al showed that  BCR-ABL1-targeting 
drugs have posititive response in many patients with Philadelphia chromosome positive (Ph+) 
CML [128]. Imatinib was one of the most successful drugs with therapeutic implications in 
leukemia. Dasatinib is another drug with huge implications in leukemia. 
Onishi et al identified and characterized a constitutively active STAT5 mutant that induces 
certain properties of malignant cells [129] and studies have identified the cause of the 
constitutive activation as being dependent on its specific role in a specific malignancy. 
Interestingly, constitutive activation of STAT5 is at times due to its induction by 
constitutively active JAK2. Indeed, the constitutive activation of STAT5 in some 
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myeloproliferative disorders is due to the JAK2 V617F mutation [130, 131]. And constitutive 
activation of STAT5 is also observed in myelodysplastic syndrome (MDS) and in 
myeloproliferative diseases, such as polycythemia vera (PV), where there is associated 
dysregulation of the upstream activating kinases, JAK1 or JAK2 [132, 133]. However, in 
AML, constitutive activation of STAT5 is driven by FLT3. FLT-3 and c-KIT gene mutations 
lead to STAT5 activation in leukemias as noted in these studies [134, 135]. Thus, activated 
FLT3 has the potential to transform hematopoietic cells and activates STAT5 in primary 
AML cells. 
Thus, a STAT5a/b targeting molecule in combination with other therapeutic agents as well as 
imatinib/dastinib could be used in leukemia.
Role in breast cancer
The STAT5 proteins are not only critical in hematopeoitic malignancies, but also in several 
other cancers and tumours. It presumably plays complex opposing roles in breast cancer (BC) 
and summarised below are the studies in breast cancer cell lines, animal models of breast 
cancer as well as human BC samples.
In studying the role of STAT5 in breast cancer, it is only justified to enlist that STAT5 plays 
an important role in proliferation, survival and terminal differentiation of the mammary gland 
[95, 136, 137]. These functions are made possible by upregulating the pro-survival genes 
(bcl-xl), as well as genes for proteins found in milk, beta-casein and whey acidic protein [95, 
138, 139]. STAT5 is a promoter of tumorigeneis in rodent mammary gland and the presence 
of STAT5a is required for the development of oncogene-induced mammary cancers in mice 
[140-142]. Knockout studies on mice indicate that a loss of STAT5a delays tumorigenesis 
and hemizygous loss of the STAT5a allele led to a delay in tumours initiation and formation 
[141, 142]. Additionally, constitutive activation of STAT5a or over expression of STAT5 led 
to the mammary tumours within 8-12 months [143]. In this study, it was noted that truncated 
STAT5 (carboxy terminal truncation) overexpression led to a poorly differentiated mammary 
tumour. Thus, it could be speculated that the poor differentiation was due to the wtSTAT5 
being inhibited and that the carboxy terminal truncated STAT5 plays an important role in 
malignancy and tumour formation. Again, Vafaizadeh et al, using a lentiviral infection 
system, created a constitutively active STAT5 (cS5-F) which upon expression, led to 
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epithelial hyperproliferation and ER+ PR+ adenocarcinomas [144]. Nonetheless, STAT5 also 
has a protective role in BC cells and although STAT5B is constitutively active in human BC 
cell lines, over expressing a dominant negative variant of STAT5 leads to an induction of 
apoptosis in luminal BC cell lines [145]. Recent work by Caffarel et al, using the constitutive 
active JAK2-V617F mutant and expressing it in MCF-7 BC cells, led to a more invasive form 
of BC in xenografts [146]. 
Thus, while knockout studies on mice and BC cell lines indicate that a loss of STAT5 delays 
tumorigenesis, this is not the case in humans. Infact, one of the most notable findings from 
clinical studies was done using immunohistochemistry to the tyrosine phorpshoryakted 
protein and it was observed that while 40% of all breast cancers displayed activation of 
STAT3 alone, only 7% of them showed STAT5 activation. Of the tumors that presented with 
activated STAT5, more than 80% had activation of STAT3 as well. Furthermore, an analysis 
of the pathological features of these tumors revealed that cancers displaying activation of 
STAT5 were more likely to be highly differentiated, low grade tumors. Additionally, they 
were less likely to form metastases to lymph nodes. All of these properties of tumors with 
activation of both STAT3 and STAT5 reflected a more favorable clinical outcome than 
tumors displaying activation of STAT3 alone. Indeed, patient survival was significantly 
prolonged when tumors displayed gene expression signatures consistent with activation of 
STAT3 and STAT5 rather than STAT3 activation alone [147]. In another study by Yamashita 
et al, STAT5 was defined as a strong prognostic molecular marker in ER-positive breast 
cancer. In this study, they studied the expression of STAT3 and STAT5 in more than 500 
breast cancer tissues by immunohistochemical techniques and observed that in ER positive 
patients having Stat5 positive tumours had significantly increased overall survival, thereby 
suggesting that expression of Stat5 is helpful in selecting patients who could possibly benefit 
from endocrine therapy [148]. These findings thus correspond to the notion that normally 
STAT5 promotes differentiation of mammary epithelium. Moreover, they also suggest that 
tumors with activation of STAT5 (or both STAT3 and STAT5) may be more susceptible to 
cell death induced by chemotherapeutic agents, which could also contribute to a more 
favorable prognosis. Various other studies go onto define the protective role of STAT5 in 
breast cancer pathogenesis. STAT5 expression and activation when studied in breast cancer 
samples showed a gradual loss of STAT5 activity during cancer progression [149]. Activated 
STAT5 was associated with a favorable prognosis in breast cancer patients [150]. Peck et al 
showed that a loss of pSTAT5 from the nucleus predicts for a poor clinical outcome along 
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with the possibility of failure to respond to endocrine therapy in ER+ve breast cancer patients 
[151]. Interestingly, the expression of Bcl6 is inhibited by prolactin mediated activation of 
STAT5 in breast cancer [152]. Again, it has been shown that the STAT3 and STAT5 
signaling pathway is integrally involved in endocrine resistance and more so in the growth 
factor-stimulated cases [153].
Thus, there appears to be a fine interplay of functional roles between STAT3 and STAT5 in 
the various breast cancer subtypes. STAT5 expression corresponds to better prognosis for 
patient survival by an increase in epithelial cell differentiation and delaying metastasis [154].
 Another aspect of STAT5 biology concerns its specificity for a specific breast cancer 
subtype and its role in endocrine resistance. In premenopausal women which are 
predominantly hormone responsive tumors or ER+ve tumors, increase in prolaction was 
associated with increased cancer rick [155].  STAT5 was found to be constitutively activated 
in ER+ ve tumours [156], and mice studies went onto demonstrate that CA-STAT5 led to the 
development of tumors in the mammary gland [157].
In 2012, Adrian Britschgi et al demostarted the fine cross talk between signalling pathways 
and that suppressing the PI3K/mTor pathway, led to an activation of the JAK2/STAT5 
pathway and circumvented the efficancy of the PI3K/mTor inhibition [158]. However, dual 
inhibition of the PI3K/mTor pathway led to a robust response with cancer cell apoptosis and 
reduction in tumor growth, leading to an increase in the overall survival. This strategy of 
combined targeting is thus a strategy to combat triple-negative breast cancer (which is 
characterized by the absence of expression of estrogen and progesterone as well as 
ERBB2/HER2 receptors), a particularly aggressive and currently incurable disease.
There remains no doubt with the conflicting studies in mice, BC cell lines and human tumour 
samples, that STAT5 plays a complex role in breast cancer. It appears to have a dual role 
dependant on the stage of tumour preogression- promoting tumour progression in the early 
stages of tumour formation while inhibiting their potential to metastasize. It could also be 
argued that STAT5A/B plays conflicting roles in human and mouse cancer tumorigenesis. 
Tang et al, on a study in BC cell lines, have reported the differential activity of STAT5a and 
STAT5b  in inducing survival and inbiting cell migration [159]. 
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Additionally, new mouse models need to be created and studied to delineate the role of 
STAT5 in BC. There is now a demand to create models where STAT5 could be knocked out 
or overexpressed in the tumour once they are formed, so as to help study its role in later 
stages of cancer progression. Another caveat to studies in breast cancer lies in the various 
subtypes of breast cancer and the complexity of the developmental process involved in the 
mammary gland. The role of STAT5 is thus context specific and targeting STAT5 could not 
only be beneficial in a subset of the breast cancer cell types but also on the stage of the 
tumour development/progression and as a combination drug.
Conclusion and future prospects
The JAK-STAT5 pathway has been associated with proliferation, survival, differentiation as 
well as apoptosis. Activation of STAT5 is dependent on the phosphorylation, acetylation, 
SUMoylation as well as ubiquitination states. The importance of tetramerization for normal 
immune functions is well understood and several cancers have shown a dependence on the 
cancer-promoting actions of STAT5. 
While hematopoietic malignancies have been studied in some detail, it is the role of STAT5 
in solid cancers and tumours, its regulation of the immune system and the anti-tumour 
response elicited which warrants further research. In brief, STAT5, by expanding regulatory 
T cells which promote tumours and cancers by inhibiting anti-tumour activity, leads to the 
progression of cancers and tumours. This very role of STAT5 could be exploited for its use as 
a therapeutic target.
Indeed, several small molecule drugs targeting the cytokine signalling as well as JAK 
inhibitors have shown promise. Discovery of small molecule therapeutic drugs to target 
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STAT5 are in progress, although a STAT5 specific inhibitor is not yet available for use in 
clinical trials. The challenge to effectively target the JAK-STAT5 pathway for cancer therapy 
remains and needs extensive research and study. 
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Table 1: Effector molecules and the kinases involved in signalling of STAT5
Ligands                   JAK's  and non JAK kinases
IL-2 JAK1, JAK3, Fyn, Lck, Hck, Tec, 
SykIL-3 JAK2, Fyn, Hck, Lyn
IL-4 JAK1, JAK3
IL-5 JAK2, Btk






IL-27 JAK1, JAK2, Tyk2
EGF JAK1, EGFR, Src
EPO JAK2, Src Family
GH JAK2, Src Family
GM-CSF JAK2, Hck, Lyn
Insulin JAK2, IR, Src
Leptin JAK2
PDGF JAK1, PDGFR, Src
PRL JAK2, Src
TPO Tyk2, JAK2, Lyn
29
Abbreviations: EGF, epidermal growth factor; EPO, erythropoietin; GH, growth hormone; 
GM-CSF, granulocyte macrophage-colony stimulating factor); PDGF, platelet-derived 
growth factor; PRL, prolactin; TPO, thrombopoietin; IL, interleukin; JAK, Janus kinase; 
STAT, signal transduction and activation of transcription; TYK, tyrosine kinase. Compiled 
from [161-163].
Table 2: Protein interaction partners of STAT5
Protein Interacting domain
BRCA1 and BRCA2 not determined
Caveolin not determined
CBP/p300 transactivation domain of STAT5a
CPAP SH2 domain of STAT5
CrkL SH2 domain of CrkL
ERK transactivation domain of STAT5a
ERα transactivation domain of STAT5
Ligand/CypB N terminus of STAT5
NcoA-1/SRC-1 transactivation domain of STAT5a
Nmi coiled-coil domain of STAT5
Oct1 transactivation domain of STAT5
p100 transactivation domain of STAT5
SMRT coiled-coil domain of STAT5
STAP-2/BKS transactivation domain of STAT5
TRβ1 non-determined 
References: [164]
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